Apogee Therapeutics, Inc. — Operating Income by Fiscal Year
4 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/3c45862f-55e7-42d8-a0de-04036fb37999/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-285.6M | 2025-01-01 – 2025-12-31 | evidence 0001974640-26-000002 |
| FY 2024 | $-216.9M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-030385 |
| FY 2023 | $-93.0M | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-002406 |
| FY 2022 | $-30.7M | 2022-02-04 – 2022-12-31 | evidence 0001558370-24-002406 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).